SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 51.59-1.1%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Ian@SI5/19/2006 8:18:09 PM
  Read Replies (1) of 52153
 
Is Diovan an NVS owned molecule? Did it come from a partner???

++++++++++++++++

03:05 ET Diovan the first blood pressure medication in a large-scale clinical trial to lower C-reactive protein, an important marker in inflammation (NVS) 56.81 :Co announces its blood pressure medication Diovan lowered the level of the inflammatory marker high sensitivity C-reactive protein (hsCRP), independently of its established efficacy in lowering blood pressure, according to findings presented at the American Society of Hypertension Annual Scientific Meeting and Exposition and published online in Hypertension later today. The study also showed that Diovan and Diovan HCT helped a significant number of hard-to-treat patients with a severe form of high blood pressure -- called "stage 2" -- quickly achieve blood pressure goals.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News